Biomea Fusion (NASDAQ:BMEA – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Biomea Fusion and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomea Fusion | N/A | -310.15% | -145.38% |
| Pluri | -1,890.59% | N/A | -99.68% |
Analyst Ratings
This is a summary of recent ratings and price targets for Biomea Fusion and Pluri, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomea Fusion | 1 | 1 | 7 | 1 | 2.80 |
| Pluri | 1 | 0 | 1 | 0 | 2.00 |
Insider and Institutional Ownership
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by company insiders. Comparatively, 25.9% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Biomea Fusion and Pluri”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomea Fusion | N/A | N/A | -$138.43 million | ($2.39) | -0.48 |
| Pluri | $1.34 million | 23.33 | -$22.58 million | ($4.92) | -0.63 |
Pluri has higher revenue and earnings than Biomea Fusion. Pluri is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Biomea Fusion has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Summary
Biomea Fusion beats Pluri on 8 of the 14 factors compared between the two stocks.
About Biomea Fusion
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
